PubMed Health⌕ Search

Biomedical subjects

H Garus

Publications and source records attributed to H Garus.

2 recordsLinked to original sources
PubMed1990

A single dose of the topical carbonic anhydrase inhibitor MK-927 decreases IOP in patients.

MK-927 is a novel topical carbonic anhydrase inhibitor (CAI). We present the first single-dose clinical trial of MK-927 in 24 patients with bilateral primary open-angle glaucoma or ocular hypertension. This investigation was conducted as a two-centre, double-masked, randomised, placebo controlled study. Patients received one drop of 2% MK-927 in one eye and placebo in the other eye. Modified diurnal intraocular pressure (IOP) curves were performed before the study and on one treatment day. A single dose of 2% MK-927 induced a peak mean IOP decrease of 10.5 mmHg at 4.5 hours postdose. With compensation for diurnal variation, as determined by the prestudy diurnal pressure curve, the net peak mean reduction of IOP caused by MK-927 was 7.5 mmHg versus a corresponding net change of 1.4 mmHg in the contralateral placebo treated eye. Thus a single dose of MK-927 gave a clinically significant IOP reduction in patients.

Carbonic Anhydrase Inhibitors↗
PubMed1990

[Decrease in intraocular pressure following administration of the local carbonic anhydrase inhibitor (MK-927)--comparison of the effect with pilocarpine].

We studied the effect of a single dose of the local carbonic anhydrase inhibitor, MK-927, on lowering IOP in 24 patients with bilateral primary open-angle glaucoma or ocular hypertension and compared it with the effect of pilocarpin in 9 patients. Following a washout of any glaucoma medication of 3 to 14 days, a diurnal IOP curve was performed. Two to seven days later one eye received a single drop of 2% MK-927 while the other eye received placebo and the diurnal IOP curve was repeated. MK-927 treated eyes showed a peak mean IOP change of 10.5 mmHg (33.1%) occurring at 4.5 h postmedication. In nine eyes treated with pilocarpin 1% q.d., the mean reduction of the mean IOP was 7.0 mmHg (22.1%) compared to no treatment. The same eyes showed a mean reduction of mean IOP of 6.1 mmHg (18.9%) following a single dose of MK-927. In contrast, the mean reduction of the maximal IOP treated with pilocarpin was 7.3 mmHg (25.8%) and 10.2 mmHg (34.2%) following MK-927. Considering the IOP lowering of MK-927 shown here, the possibility of a topically effective glaucoma therapy by local carbonic anhydrase inhibitor seems to be established. The IOP lowering effect of MK-927 appears to be similar to that of pilocarpin 1%.

Carbonic Anhydrase Inhibitors↗